News brief.
Massachusetts voters in November narrowly defeated a sweeping measure that would have stopped all conversions of nonprofit hospitals and health plans until the state created a system guaranteeing comprehensive, high quality health care coverage, but the concept lives on. Some details in the defeated referendum may not survivesuch as banning financial incentives to curb patient care and insisting that 90 cents of each premium dollar be spent on actual carebut a business-heavy state task force is still pursuing the goal of coverage for every resident. "What we're trying to do now is get the private marketplace and legislators and regulators to be more creative," explains task force member Susan Connolly, a consultant with the William M. Mercer office in Boston. The group may back low-cost, limited-network policiesnot at all in the established Massachusetts stylethat, for instance, would not include access to teaching hospitals. And it is focusing on how to get younger workers, especially males, to sign up for policies that are already available to them.
Daniel Moskowitz. Massachusetts plugs away at universal coverage. Business and Health 2001;1:15.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More